Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of STSA-1002 Subcutaneous Injection in Healthy Subjects
NCT05702983Phase 1Completed
- Sponsor
- Staidson Biopharmaceutical
- Start
- Jan 2023
- Primary completion
- Apr 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of STSA-1002 in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) (2 cohorts), sponsored by Staidson Biopharmaceutical. Primary endpoints: Number of treatment-related adverse events at 50 days, Abnormal clinical laboratory values at 50 days and 13 more. Started Jan 2023; status: completed.
02
Drugs
STSA-1002
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT05702983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05702983.